Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 685-691 , December 2009

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions

  • Alberto Ocaña

      Affiliations

    • Drug Development Program, Princess Margaret Hospital, Toronto, Canada
    • Albacete University Hospital and AECC unit, Albacete, Spain
    • Corresponding Author InformationCorresponding author. Address: Drug Development Program, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, Canada M5G 2M9. Tel.: +1 4169464501x5717.
    • ,
  • Eitan Amir

      Affiliations

    • Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada

Received 25 July 2009 ,Accepted 3 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0305-7372(09)00115-7

doi: 10.1016/j.ctrv.2009.08.001

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 685-691 , December 2009

Article Tools

* Image Usage & Resolution